Bullet point summary
What is already known
Montelukast is an antagonist of the cysteinyl leukotrienes receptor 1,
widely used in asthma management.
Montelukast has been identified as an inhibitor of new targets
involved in neurodegenerative disorders.
What this study adds
Montelukast modulates the amyloid clearance pathway.
Central catabolic pathways are also modulated by montelukast.
Clinical significance
The identified pathways affected by montelukast support the drug’s
repurposing for Alzheimer’s disease management.